

SAFETY DATA SHEET



* 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material	BETNOVATE LOTION
Synonym(s)	BETNOVATE 0.1% LOTION * BETNELAN LOTION 1 MG/ML * BETNEVAL LOTION 0.1% * BETNESOL-V LOTION * BETNOVAT KUTAN SOLUTION 1 MG/ML * BETNOVAT SOLUTION * BETNOVAT LOTION * ECOVAL LOZIONE 0.1% * BETAMETHASONE VALERATE, FORMULATED PRODUCT
Company Name	<p>GlaxoSmithKline, Corporate Environment, Health & Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK</p> <p>UK General Information: +44-20-8047-5000 Transport Emergency (EU) +44-1865-407333 Medical Emergency +1-612-221-3999, Ext 221 Information and Advice: US number, available 24 hours Multi-language response</p> <p>GlaxoSmithKline, Corporate Environment, Health & Safety One Franklin Plaza, 200 N 16th Street Philadelphia, PA 19102-1225 US</p> <p>US General Information: +1-888-825-5249 Transport Emergency (non EU) +1-703-527-3887 US number, available 24 hours Multi-language response</p>

* 2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
BETAMETHASONE VALERATE	2152-44-5	0.12	
ISOPROPYL ALCOHOL	67-63-0	5.1	200-661-7
NON-HAZARDOUS INGREDIENTS	Unassigned	94.78	

3. HAZARDS IDENTIFICATION

Fire and Explosion	This product is classified as flammable.
Health	Caution - Potent pharmaceutical agent. Health effects information is based on hazards of components. May cause steroid withdrawal rash.
Environment	No information is available about the potential of this product to produce adverse environmental effects.

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
------------------	---

Material BETNOVATE LOTION

Inhalation	Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
Eye Contact	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre. Medical treatment in cases of overexposure should be treated as an overdose of glucocorticosteroid.
Medical Conditions Caused or Aggravated by Exposure	Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product.
Antidotes	No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards	This product is flammable. Fire and explosions might result if vapours are allowed to accumulate in the vicinity of a source of ignition.
Extinguishing Media	Carbon dioxide, dry powder or foam extinguishers are recommended. Do not use water extinguishers. Water jets may intensify the fire or be ineffective.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal. Move containers from the fire area if possible without increased personal risk.
Hazardous Combustion Products	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Stop leak and eliminate all sources of ignition (no smoking, sparks or flames). Fence or cordon the affected area and do not allow individuals to touch or walk through the spilled material unless wearing appropriate protective clothing. Wear protective clothing and equipment consistent with the degree of hazard. Vapour-suppressing foam or water spray may be used to control vapours as appropriate.
Environmental Precautions	Prevent entry into waterways, sewers, surface drainage systems and poorly ventilated areas.
Clean-up Methods	Spread an inert absorbent on the spill and place in a suitable, properly labelled container for recovery or disposal. Equipment used for clean-up should be earthed (grounded) and non-sparking.
Decontamination Procedures	No specific decontamination or detoxification procedures have been identified for this product. Detergent solutions can be used for clean-up and decontamination operations.

7. HANDLING AND STORAGE

HANDLING

General Requirements	Ensure that any area in which this material is handled has sufficient ventilation to avoid the build up of vapour and to control employee potential exposure to volatiles below National Occupational Exposure Limits.
Ignition Controls	Keep this material away from all forms of ignition such as open flames, mechanical sparks, frictional heat and hot surfaces.

STORAGE

Keep material in sealed containers in a cool, well-ventilated area away from sources of ignition.

Material BETNOVATE LOTION

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

INGREDIENT	BETAMETHASONE VALERATE	
GSK Occupational Hazard Category	4	
GSK Occupational Exposure Limit	10 mcg/m ³ (8 HR TWA)	SKIN
ENGINEERING CONTROLS		
Exposure Controls	An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Refer to the Exposure Control Matrix for more information about how ECA's are assigned and how to interpret them.	
Other Equipment or Procedures	Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.	

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	
Physical Form	Liquid.
Flash Point	21 to 55 °C (Estimation based on components).

10. STABILITY AND REACTIVITY

Stability	This product is expected to be stable.
Conditions to Avoid	Avoid direct sunlight, conditions that might generate heat and sources of ignition.

11. TOXICOLOGY INFORMATION

Pharmacological Effects	This material is a selective glucocorticoid receptor agonist. Adverse effects of overexposure might include: suppression of adrenal glands; temporary decrease in white blood cell counts; symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing); increased susceptibility to infection.
Target Organ Effects	Adverse effects might occur in the following organ(s) following overexposure: adrenal glands; immune system.
Routes of Exposure	
Oral Toxicity	Not expected to be toxic following ingestion.
Skin Effects	Irritation is not expected following direct contact. Pharmacological effects may occur following skin absorption.
Eye Effects	Minor irritation might occur following direct contact with eyes.
Sensitisation	Allergic skin reactions might occur following dermal exposure. Assessment based upon information from human exposure.
Genetic Toxicity	Not expected to be genotoxic under occupational exposure conditions.
Carcinogenicity	Not expected to produce cancer in humans under occupational exposure conditions. No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.
Reproductive Effects	Not expected to produce adverse effects on fertility or development under occupational exposure conditions.
Other Adverse Effects	None known for occupational exposure.

12. ECOLOGICAL INFORMATION

Summary	This material contains an active pharmaceutical ingredient that has been tested, and which may be toxic to aquatic organisms if released directly to the environment. Appropriate precautions should be taken to limit release of this material to the environment. Local regulations and procedures should be consulted prior to environmental release. Specific information on the active pharmaceutical ingredient is provided below.
----------------	---

Material BETNOVATE LOTION

ECOTOXICITY**Aquatic**

Ecotoxicity	This material contains an active pharmaceutical ingredient that may be toxic to aquatic organisms.
Activated Sludge Respiration	This material contains an active pharmaceutical ingredient that is not toxic to activated sludge microorganisms. IC50: > 1000 mg/l, 3 Hours, Activated sludge NOEC: 1000 mg/l, 3 Hours, Activated sludge
Daphnid	This material contains an active pharmaceutical ingredient that is toxic to daphnids. EC50: 1.9 mg/l, 48 Hours, Daphnia magna, Static test NOEC: 0.5 mg/l, 48 Hours, Daphnia magna, Static test

MOBILITY

Adsorption	This material contains an active pharmaceutical ingredient that is likely to adsorb to soil or sediment. This material contains an active pharmaceutical ingredient that is likely to adsorb to sludges and other biomass.
Partitioning	This material contains an active pharmaceutical ingredient with octanol/water partition coefficient data that suggests that for environmental fate predictions the active pharmaceutical ingredient may have the tendency to distribute into fats.

PERSISTENCE/DEGRADATION

Hydrolysis	This material contains an active pharmaceutical ingredient that has been shown to be chemically unstable in water. Hydrolysis may be a significant depletion mechanism. Half-Life, Neutral: 6.5 Days, Measured, pH 7 Buffer Solution
Biodegradation	This material is inherently biodegradable. Aerobic - Inherent Percent Degradation: 28 %, 28 days, Modified MITI (II) Test., Activated sludge

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used. Wherever possible, disposal should be in an on-site licenced chemical incinerator, if allowed by the incinerator licence or permit. If no on-site incinerator is available, dispose of material in a licenced commercial chemical incinerator.

Regulatory Requirements Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information This product is not regulated according to IATA, IMDG, US DOT or ADR/RID requirements.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)

Classification This product is classified as hazardous according to the OSHA Hazard Communication Standard.

Other US Regulations

TSCA Status Exempt

16. OTHER INFORMATION

References GSK Hazard Determination

SDS Version Number 7

SDS Sections Updated**Sections**

COMPOSITION / INFORMATION ON INGREDIENTS

IDENTIFICATION OF SUBSTANCE / PREPARATION AND OF
COMPANY**Subsections**

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.